Search results
Showing 556 to 570 of 1455 results for do not do recommendations
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referra...
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)
This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.
View quality statements for QS147Show all sections
Sections for QS147
This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.
View quality statements for QS63Show all sections
Sections for QS63
- Quality statements
- Quality statement 1: Assessing recent changes that may indicate delirium
- Quality statement 2: Interventions to prevent delirium
- Quality statement 3: Use of antipsychotic medication for people who are distressed
- Quality statement 4: Information and support
- Quality statement 5: Communication of diagnosis to GPs
- Update information
- About this quality standard
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)
Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke
People and communities - putting you at the heart of our work
products are focused around the people most directly affected by our recommendations. Involving you in the development of our guidance We
People and communities - putting you at the heart of our work
products are focused around the people most directly affected by our recommendations. Involving you in the development of our guidance We
research recommendations. Read our process and methods guide (PDF). Browse the list below to find a topic of interest. Only research...
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.